1. Home
  2. GCTK vs CDT Comparison

GCTK vs CDT Comparison

Compare GCTK & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GlucoTrack Inc.

GCTK

GlucoTrack Inc.

HOLD

Current Price

$0.33

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$0.49

Market Cap

2.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCTK
CDT
Founded
2001
2019
Country
United States
United States
Employees
N/A
4
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
2.4M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
GCTK
CDT
Price
$0.33
$0.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
404.1K
12.2M
Earning Date
05-13-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.65
N/A
Revenue
$589,462.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.12
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.37
52 Week High
$14.14
$11.00

Technical Indicators

Market Signals
Indicator
GCTK
CDT
Relative Strength Index (RSI) 31.05 35.84
Support Level $0.29 N/A
Resistance Level $0.73 $0.73
Average True Range (ATR) 0.03 0.23
MACD 0.00 0.01
Stochastic Oscillator 9.47 1.87

Price Performance

Historical Comparison
GCTK
CDT

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.

Share on Social Networks: